INGELHEIM, Germany, April 2 (Reuters) - Germany's largest pharmaceutical company Boehringer Ingelheim on Wednesday reported a currency-adjusted 6.1% gain in 2024 revenues, buoyed by diabetes drug ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback